Breakthrough immunotherapy company launches its Scientific Advisory Board with the appointment of Nobel Prize winner Harold Varmus
CAMBRIDGE, Massachusetts, July 19, 2016 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), co-founded in July 2015 by Dr. Tyler Jacks of the Massachusetts Institute of Technology, Dr. David Raulet of UC, Berkeley, and William Haney, its Chief Executive Officer, today announced the formation of its Scientific Advisory Board with the appointment of Nobel Laureate, Harold Varmus.
"For over four decades, Harold has been a visionary in cancer biology and cancer genetics," said co-founder Dr. Tyler Jacks. "I have had the pleasure of working closely with Harold for many years, and we at Dragonfly are thrilled to have one of the world's leading thinkers on cancer join our Scientific Advisory Board."
Harold Varmus, M.D. is a cancer biologist and virologist, who has served as Director of the National Cancer Institute and the National Institutes of Health. In 1989, he was a co-recipient, with J. Michael Bishop, of a Nobel Prize in Physiology or Medicine for the discovery of the cellular origin of retroviral oncogenes. He is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a Senior Associate at the New York Genome Center. He also serves as a member of the Secretary of Energy's Advisory Board, the Global Health Advisory Board at the Bill and Melinda Gates Foundation, the Lasker Foundation Prize Jury, and the Scientific Advisory Board of the Broad Institute at Harvard and MIT.
"I am pleased to join Tyler Jacks, whom I have known since he was a graduate student in my laboratory at UCSF, and David Raulet in serving on Dragonfly's Scientific Advisory Board," said Dr. Varmus. "The development of new immunotherapies for cancer is very timely, and I am pleased to advise Dragonfly about their efforts."
About Dragonfly Therapeutics Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients.